Induction-maintenance therapy for HIV-1 infection

Future HIV Therapy

Volumn 2, Issue 2, 2008, Pages 175-185

  Curlin, Marcel E ^a   Wilkin, Timothy ^b   Mittler, John ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral drugs; Drug resistance; Drug therapy; HIV 1; Induction maintenance; Mathematical model

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALKYLATING AGENT; AMINOSALICYLIC ACID; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; ASPARAGINASE; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOSERINE; EFAVIRENZ; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MERCAPTOPURINE; METHOTREXATE; NELFINAVIR; PREDNISONE; PROTEINASE INHIBITOR; PYRAZINAMIDE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STREPTOMYCIN; UNINDEXED DRUG; VINCA ALKALOID; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG COST; DRUG WITHDRAWAL; HEARING DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER DYSFUNCTION; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; NEUROPATHY; PATIENT COMPLIANCE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VESTIBULAR DISORDER; VIRUS LATENCY; VIRUS LOAD; VIRUS REPLICATION;

EID: 52349092643     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.2.175     Document Type: Review

References (47)

1. Danel C, Moh R, Minga A et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367, 1981-1989 (2006).
2. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2286-2296 (2006).
3. Pai NP Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL: Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst. Rev. 3, CD005482 (2005).
4. Hirschel B: Beware of drug holidays before HIV salvage therapy. N. Engl. J. Med. 349, 827-828 (2003).
5. Asheshov IN, Strelitz F: An antibiotic substance active agains mycobacterium tuberculosis. Science 101, 119-120 (1945).
6. Youmans GP, Raleigh GW, Youmans AS: The tuberculostatic action of para-aminosalicylic acid. J. Bacteriol. 54, 409-416 (1947).
7. Yeager RL, Munroe WG, Dessau FJ: Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65, 523-546 (1952).
8. Donaldson RI: Clinical study of the use of para-aminosalicylic acid in the treatment of pulmonary tuberculosis. Edinburgh Med. J. 56, 245-249 (1949).
9. Albouy R, Eloy P, Pestel M, Ravina A, Rey M: First clinical results obtained with cycloserine in the treatment of human tuberculosis. Antibiot. Annu. 3, 148-152 (1955).
10. Mitchison DA: Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis; results of simultaneous sensitivity tests in liquid and on solid media. Thorax 5, 144-161 (1950).
11. Turnbull FW, Wallace AT, Stewart S, Crofton JW: Streptomycin resistance in patients with pulmonary tuberculosis previously treated with P.A.S. alone. Br. Med. J. 1, 1244-1246 (1953).
12. Daniels M, Hill AB: Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials. Br. Med. J. 1, 1162-1168 (1952).
13. Frappier A, Desjardins R, Panisset M: Primary resistance of tubercle bacilli to streptomycin and other antituberculous agents in the province of Quebec. Can. Med. Assoc. J. 76, 653-655 (1957).
14. Lewin N, Aronovitch M: Para-aminosalicylic acid with streptomycin in pulmonary tuberculosis. Can. Med. Assoc. J. 65, 140-144 (1951).
15. No authors listed. PREVENTION of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation. Br. Med. J. 1, 1157-1162 (1952).
16. No authors listed. ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br, Med. J. 2, 1005-1014 (1953).
17. No authors listed. PROGRESS report on therapeutic and toxic effects of combinations of isoniazid, streptomycin, and para-aminosalicylic acid; United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis. Am. Rev. Tuberc. 69, 1-12 (1954).
18. Lubing HN: Peripheral neuropathy in tuberculosis patients treated with isoniazid. Am. Rev. Tuberc. 68, 458-461 (1953).
19. Linton WS, Rabinovitz E, Olie M: Isonicotinic acid hydrazide; some sensory disturbances during therapy. S. Afr. Med. J. 26, 889-890 (1952).
20. Coates EO Jr, Brickman GL, Meade GM: Toxicity of isonicotinic acid hydrazides in pulmonary tuberculosis; toxicity of isoniazid and iproniazid used alone and in combination with streptomycin or p-aminosalicylic acid. AMA Arch. Intern. Med. 93, 541-549 (1954).
21. Sacks MS, Bradford GT, Spurling CL: Aplastic anemia complicating streptomycin treatment of pulmonary tuberculosis; report of a case, with recovery. JAMA 147, 308-311 (1951).
22. Mitchison DA: The diagnosis and therapy of tuberculosis during the past 100 years. Am. J. Respir. Crit. Care Med. 171, 699-706 (2005).
23. Frei E 3rd, Karon M, Levin RH et al.: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26, 642-656 (1965).
24. Simone JV: History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract. Res. Clin. Haematol. 19(2), 353-359 (2006).
25. Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 90, 4243-4251 (1997).
26. Brenner H, Kaatsch P, Burkhardt-Hammer T et al.: Long-term survival of children with leukemia achieved by the end of the second millennium. Cancer 92, 1977-1983 (2001).
27. Ho DD: Time to hit HIV, early and hard. N. Engl. J. Med. 333, 450-451 (1995).
28. Perelson AS, Essunger P, Cao Y et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
29. Raijers MH, Weverling GJ, Jurriaans S et al.: Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 352, 185-190 (1998).
30. Pialoux G, Raffi F, Brun-Vezinet F et al.: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N. Engl. J. Med. 339, 1269-1276 (1998).
31. Havlir DV, Marschner IC, Hirsch MS et al.: Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N. Engl. J. Med. 339, 1261-1268 (1998).
32. Kahiert C, Hupfer M, Wagels T et al.: Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection. AIDS 18, 955-957 (2004).
33. Arribas JR, Pulido F, Delgado R et al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 vital suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J. Acquir. Immune Defic. Syndr. 40, 280-287 (2005).
34. Markowitz M, Hill-Zabala C, Lang J et al.: Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 39, 257-264 (2005).
35. Swindells S, DiRienzo AG, Wilkin T et al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296, 806-814 (21)06).
36. Pulido F, Arribas JR, Delgado R et al.: Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22, F1-F9 (2008).
37. Busti AJ, Hall RG, Margolls DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24, 1732-1747 (2004).
38. Stevens R, Kakuda T, Bertz R, Rode R, Kempf D: Inhibitory quotient of protease inhibitors using a standardized determination of IC50. Presented at: 4th International Workshop on the Clinical Pharmacology of HIV Therapy. Cannes, France, 27-29 March 2003.
39. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512-517 (1999).
40. Nowak MA, Bonhoeffer S, Shaw GM, May RM: Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. Theor. Biol. 184, 203-217 (1997).
41. Ribeiro RM, Bonhoeffer S: Production of resistant HIV mutants during antiretroviral therapy. Proc. Natl Acad Sci. USA 97, 7681-7686 (2000).
42. Curlin ME, Iyer S, Mittler JE: Optimal timing and duration of induction therapy for HIV-1 Iinfection. PLoS Comput. Biol. 3, e133 (2007).
43. Andries K, Azijn H, Thielemans T et al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48, 4680-4686 (2004).
44. Vingerhoets J, Azijn H, Fransen E et al.: TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79, 12773-12782 (2005).
45. Campo RE, Lalanne R, Tanner TJ et al.: Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 19, 447-449 (2005).
46. Vernazza P, Daneel S, Schiffer V et al.: The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21, 1309-1315 (2007).
47. Salomon H, Wainberg MA, Brenner B et al.: Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14, F17-F23 (2000).